Solaris Pharma Corporation

Solaris Pharma Corporation, founded in 2018, is a privately held, revenue-generating company specializing in complex generic and specialty pharmaceuticals. Its strategy centers on developing difficult-to-manufacture products in dosage forms like topicals, sterile injectables, and tablets, which face high development hurdles but offer attractive market opportunities with limited competition. Led by CEO Shalin Jani, the company has a validated development process, multiple product approvals, and a commercial track record, positioning it as a dependable supplier in a niche segment of the pharmaceutical industry.

Integrated expertise in formulation, process development, regulatory strategy, and scale-up for complex generic and specialty pharmaceutical dosage forms (sterile, topical, tablets).

Solaris competes in the complex generic pharmaceutical sector against other specialized generic companies and the R&D arms of large generic manufacturers. Its competitive advantage is its focused expertise and efficient development process for high-barrier products, allowing it to target niches that larger firms may overlook and that are too difficult for smaller, less-experienced firms.